Increased Entropy Predicts Adverse Cardiac Events in Patients with High Cardiovascular Risk and Hypertension: A Novel Imaging Parameter Derived from Late Gadolinium Enhancement

熵增预测高心血管风险和高血压患者的不良心脏事件:一种源自延迟钆增强的新型影像学参数

阅读:1

Abstract

BACKGROUND: Entropy derived from late gadolinium enhancement (LGE) has been shown to correlate with major adverse cardiac events (MACEs) in various cardiac diseases. However, the association between myocardial entropy and MACEs in patients with hypertension (HTN) has not been reported. METHODS: This study recruited 190 patients with high cardiovascular risk and essential HTN who underwent cardiac magnetic resonance (CMR) examination in our hospital between January 2020 and June 2024. HTN patients were followed up for MACEs, which were defined as hospitalization for the occurrence of heart failure, acute coronary syndromes, stroke, or all-cause death. Patients were divided into MACE and non-MACE groups. Cardiac morphology, function, and tissue characteristics were assessed using CMR, and left ventricular (LV) entropy was acquired from LGE images. RESULTS: Of the 190 patients with HTN, 54 (28.4%) experienced a MACE over a median follow-up period of 12.0 (8.0-27.0) months. LV entropy was significantly higher in patients with MACEs than those without (5.75 ± 0.89 vs. 5.12 ± 1.26; p < 0.001). Furthermore, LV entropy was an independent predictor of MACE, even after adjustment for clinical risk factors (odds ratio: 1.569 (1.039-2.369); p = 0.032). Receiver operating characteristic curve (ROC) analysis showed the predictive value of LV entropy, with an area under the curve (AUC) of 0.663. Adding LV entropy to the clinical model resulted in a relatively higher AUC (0.813 vs. 0.806) for the prediction of MACEs; however, this was not significantly different from the clinical model alone (p = 0.570). CONCLUSIONS: HTN patients with MACEs presented higher LV entropy than patients without MACEs. Furthermore, as an independent predictor of MACEs, LV entropy may help the risk stratification of HTN patients with high cardiovascular risk. CLINICAL TRIAL REGISTRATION: ChiCTR2100049160, https://www.chictr.org.cn/showproj.html?proj=130381.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。